Nasiflair (Chlorphenamine Maleate, Sodium Cromoglicate)

Chlorphenamine maleate is an H1‑receptor antagonist. By blocking H1 histamine receptors on nasal mucosal cells, it prevents histamine‑induced vasodilation, increased permeability and nerve stimulation, which are responsible for itching, sneezing and nasal congestion during an allergic response.

The exact dosing regimen for Nasiflair is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and not exceed the recommended number of sprays per day.

Safety data for chlorphenamine maleate and sodium cromoglicate in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against any possible risks before recommending Nasiflair to pregnant or nursing women. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nasiflair combines an H1‑antihistamine (chlorphenamine) with a mast‑cell stabiliser (sodium cromoglicate), offering both immediate symptom relief and longer‑term reduction of mediator release. Some alternatives contain only an antihistamine, which may provide rapid relief but lack the additional mast‑cell stabilising effect that can help prevent symptom recurrence.

Store Nasiflair at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain spray integrity.

Nasiflair is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

The most serious risks include severe allergic reactions such as anaphylaxis, significant nasal bleeding, and swelling of the face, lips, tongue or throat that could compromise breathing. Immediate medical attention is required if any of these symptoms occur.

Nasiflair should be avoided in individuals with known hypersensitivity to chlorphenamine, sodium cromoglicate or any formulation excipients. It is also contraindicated in patients who have experienced severe reactions to other antihistamines or mast‑cell stabilisers, and in those for whom the prescriber determines the risks outweigh the benefits.